| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print December 28, 2007
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review Article |
From the Department of Pathology,
*Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; the Department of Medical Oncology,
Dana-Farber Cancer Institute, Boston, Massachusetts; and the Department of Internal Medicine,
Baylor University Medical Center, Dallas, Texas
Abstract
Molecular classification of colorectal cancer is evolving. As our understanding of colorectal carcinogenesis improves, we are incorporating new knowledge into the classification system. In particular, global genomic status [microsatellite instability (MSI) status and chromosomal instability (CIN) status] and epigenomic status [CpG island methylator phenotype (CIMP) status] play a significant role in determining clinical, pathological and biological characteristics of colorectal cancer. In this review, we discuss molecular classification and molecular correlates based on MSI status and CIMP status in colorectal cancer. Studying molecular correlates is important in cancer research because it can 1) provide clues to pathogenesis, 2) propose or support the existence of a new molecular subtype, 3) alert investigators to be aware of potential confounding factors in association studies, and 4) suggest surrogate markers in clinical or research settings.
This article has been cited by other articles:
 |
|
 |
|
  K. Yagi, K. Akagi, H. Hayashi, G. Nagae, S. Tsuji, T. Isagawa, Y. Midorikawa, Y. Nishimura, H. Sakamoto, Y. Seto, et al. Three DNA Methylation Epigenotypes in Human Colorectal Cancer Clin. Cancer Res., January 1, 2010; 16(1): 21 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Banck and A. Grothey Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer Clin. Cancer Res., December 15, 2009; 15(24): 7492 - 7501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. Hollis, L. B. Saltz, R. J. Mayer, P. Schaefer, R. Whittom, A. Hantel, et al. KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 Clin. Cancer Res., December 1, 2009; 15(23): 7322 - 7329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kure, K. Nosho, Y. Baba, N. Irahara, K. Shima, K. Ng, J. A. Meyerhardt, E. L. Giovannucci, C. S. Fuchs, and S. Ogino Vitamin D Receptor Expression Is Associated with PIK3CA and KRAS Mutations in Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2765 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Nosho, N. Irahara, K. Shima, Y. Baba, G. J. Kirkner, J. A. Meyerhardt, and C. S. Fuchs Prognostic Significance and Molecular Associations of 18q Loss of Heterozygosity: A Cohort Study of Microsatellite Stable Colorectal Cancers J. Clin. Oncol., September 20, 2009; 27(27): 4591 - 4598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Baba, K. Nosho, K. Shima, E. Freed, N. Irahara, J. Philips, J. A. Meyerhardt, J. L. Hornick, R. A. Shivdasani, C. S. Fuchs, et al. Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer Clin. Cancer Res., July 15, 2009; 15(14): 4665 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Sepulveda, D. Jones, S. Ogino, W. Samowitz, M. L. Gulley, R. Edwards, V. Levenson, V. M. Pratt, B. Yang, K. Nafa, et al. CpG Methylation Analysis--Current Status of Clinical Assays and Potential Applications in Molecular Diagnostics: A Report of the Association for Molecular Pathology J. Mol. Diagn., July 1, 2009; 11(4): 266 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. TRIANTAFILLIDIS, G. NASIOULAS, and P. A. KOSMIDIS Colorectal Cancer and Inflammatory Bowel Disease: Epidemiology, Risk Factors, Mechanisms of Carcinogenesis and Prevention Strategies Anticancer Res, July 1, 2009; 29(7): 2727 - 2737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, K. Nosho, N. Irahara, S. Kure, K. Shima, Y. Baba, S. Toyoda, L. Chen, E. L. Giovannucci, J. A. Meyerhardt, et al. A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases Clin. Cancer Res., July 1, 2009; 15(13): 4431 - 4438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nosho, K. Shima, N. Irahara, S. Kure, Y. Baba, G. J. Kirkner, L. Chen, S. Gokhale, A. Hazra, D. Spiegelman, et al. DNMT3B Expression Might Contribute to CpG Island Methylator Phenotype in Colorectal Cancer Clin. Cancer Res., June 1, 2009; 15(11): 3663 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, K. Nosho, G. J. Kirkner, K. Shima, N. Irahara, S. Kure, A. T. Chan, J. A. Engelman, P. Kraft, L. C. Cantley, et al. PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer J. Clin. Oncol., March 20, 2009; 27(9): 1477 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Nosho, G. J Kirkner, T. Kawasaki, J. A Meyerhardt, M. Loda, E. L Giovannucci, and C. S Fuchs CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer Gut, January 1, 2009; 58(1): 90 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, K. Nosho, J. A. Meyerhardt, G. J. Kirkner, A. T. Chan, T. Kawasaki, E. L. Giovannucci, M. Loda, and C. S. Fuchs Cohort Study of Fatty Acid Synthase Expression and Patient Survival in Colon Cancer J. Clin. Oncol., December 10, 2008; 26(35): 5713 - 5720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogino, K. Nosho, G. J. Kirkner, T. Kawasaki, A. T. Chan, E. S. Schernhammer, E. L. Giovannucci, and C. S. Fuchs A Cohort Study of Tumoral LINE-1 Hypomethylation and Prognosis in Colon Cancer J Natl Cancer Inst, December 3, 2008; 100(23): 1734 - 1738. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
